Eli Lilly – Page 13

Eli Lilly Expands Manufacturing Capacity with Nexus Plant Acquisition Amid Ongoing Mounjaro and Zepbound Supply Challenges

1 year ago talkbio0Tagged Acquisition (action), Capacity, Drug Industry, Drug shortages, Eli, Eli Lilly, Manufacture, Mounjaro, Nexus manufacturing, Plants, Wisconsin, Zepbound

Eli Lilly, Nexus manufacturing plant, Wisconsin, Mounjaro, Zepbound, drug shortages, manufacturing capacity, pharmaceutical industry, acquisition

Eli Lilly Anticipates Zepbound Label Expansion Following Positive Phase III Sleep Apnea Study Results

1 year ago talkbio0Tagged Eli, Eli Lilly, expansion, Identifier, Improvement, Phase III Sleep Apnea Study, Sleep Apnea, Obstructive, SURMOUNT-OSA, Symptoms, Zepbound

Eli Lilly, Zepbound (tirzepatide), Phase III Sleep Apnea Study, SURMOUNT-OSA, Obstructive Sleep Apnea (OSA), Label Expansion, Fast Track Designation, Symptom Improvement

Metsera Emerges with $290M to Rival Obesity Pharmaceutical Giants Lilly and Novo

1 year ago talkbio0Tagged Eli Lilly, Metsera, Novo, Obesity, Phase I injectable, Product containing glucagon-like peptide 1 receptor agonist (product)

Metsera, $290M funding, Obesity treatment, Challenge Lilly and Novo, GLP-1 receptor agonist (Phase I injectable)

Eli Lilly’s Zepbound Shows Promising Results in Reducing Sleep Apnea Severity in Pivotal Trials

1 year ago talkbio0Tagged Continuous Positive Airway Pressure, Eli, Eli Lilly, Glucagon-Like Peptide-1 Receptor, Obesity, Sleep Apnea, Obstructive, tirzepatide, trials, Weight Loss, Zepbound

Eli Lilly, Zepbound, Sleep Apnea, Obstructive Sleep Apnea (OSA), Pivotal Trials, Obesity, GLP-1 Receptor Agonist, Tirzepatide, CPAP, Weight Loss